29 March 2021 - The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK?

From COVID-19 and Brexit, to the emergence of patient-centric drug development and personalised medicine, the life sciences sector has experienced a complete transformation in recent years.

The NICE methods and process review, then, represents an opportunity to update, renew, and create a modern, world-class appraisals process that fosters innovation and shows the global life sciences sector that UK plc is open for business, says Dr Catchpole.

Read Pharmaphorum article